Published by Global Data on 23rd October 2018 | Ref: 1086210 | This Report Is In Stock
BeyondSpring Inc (BeyondSpring) is a clinical stage biopharmaceutical company focused on the development of immune-oncology cancer therapies. The company offers lead compound, Plinabulin, is derived from a natural compound which holds a number of biochemical activities and provides multiple potential therapeutic potentials in various types of cancers; BPI-002, an oral small molecule agent used for the treatment of colon cancer; BPI-003 and BPI-004 against various tumors. Its target areas include non-small cell lung cancer, neutropenia prevention, and plinabulin + nivolumab. The company holds a license from the Fred Hutchinson Cancer Research Center and University of Washington for a range of platform technology which concentrates on a novel mechanism to inhibit a various oncogenes. BeyondSpring is headquartered in New York, the US.
BeyondSpring Inc (BYSI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BeyondSpring Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
BeyondSpring Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
BeyondSpring Pharma Acquires Rights to Plinabulin from Nereus Pharma 11
Venture Financing 12
BeyondSpring Pharma Raises USD20 Million in Series A Financing 12
Private Equity 13
BeyondSpring Pharma Raises USD15.3 Million in Equity Financing 13
BeyondSpring Pharma Enters into Agreement with Fred Hutchinson Cancer Research Center 14
Equity Offering 15
BeyondSpring to Raise USD20 in Private Placement of Shares 15
BeyondSpring Prices Private Placement of Shares for USD50.8 Million 16
BeyondSpring Prices IPO for USD3.5 Million 18
BeyondSpring Inc - Key Competitors 20
BeyondSpring Inc - Key Employees 21
BeyondSpring Inc - Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Jun 21, 2018: BeyondSpring Provides Operational Updates and First-Quarter 2018 Financial Results 23
Apr 03, 2018: BeyondSpring Provides Operational Update and Fourth-Quarter and Full-Year 2017 Financial Results 25
Nov 09, 2017: BeyondSpring Reports Third Quarter 2017 Operational and Financial Results 27
Aug 21, 2017: BeyondSpring Provides Operational Update for Second Quarter of 2017 28
May 22, 2017: BeyondSpring Reports First Quarter 2017 Financial Results 30
Apr 28, 2017: BeyondSpring Provides Quarterly Operational Update and Full Year 2016 Results 32
Corporate Communications 35
Aug 01, 2018: Beyondspring appoints Richard J. Daly as chief operating officer to lead the transition to commercialization 35
Mar 27, 2018: BeyondSpring Names Edward Dongheng Liu As Chief Financial Officer 36
Jan 03, 2018: BeyondSpring Appoints Life Sciences Veteran Patrick Fabbio to Board of Directors as an Independent Member 37
Product News 38
01/10/2017: BeyondSpring to Present at Biotech Showcase 2017 During Annual JPMorgan Healthcare Conference on January 10 in San Francisco 38
Product Approvals 39
Jan 24, 2017: FDA Accepts BeyondSpring IND Application for Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia 39
Clinical Trials 40
Feb 21, 2017: BeyondSprings Promising Clinical Data for Lead Asset on Non-Small Cell Lung Cancer Treatment Selected for Presentation at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium 40
About GlobalData 41
Contact Us 41
1086210 | GDPH2346923D
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Buy now using our secure payment system.